S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Servier Standardizes Global Data Foundation with Veeva OpenData

Eighty-nine percent of artificial intelligence initiatives across the pharmaceutical industry fail due to fragmented data, a hurdle Servier aims to clear by adopting Veeva OpenData. The French pharmaceutical company is standardizing its customer reference data across 80 countries to create a unified foundation for scaling AI-driven commercial operations.

Servier Standardizes Global Data Foundation with Veeva OpenData
Photo: Bio & News

By integrating Veeva OpenData with its existing deployment of Veeva Link Key People, Servier is replacing isolated regional silos with a consistent, global semantic layer. This move allows the company to connect commercial and medical teams through a single source of high-quality information, ensuring consistent engagement with healthcare professionals regardless of the market. Liam Hanrahan, director of world operations excellence at Servier, noted that the transition provides the necessary infrastructure to scale AI capabilities effectively.

Kilian Weiss, president of Link and OpenData at Veeva, highlighted that Servier’s decision reflects a shift toward a data-first strategy, which is critical for moving beyond experimental AI projects. As part of the broader Veeva Data Cloud, this harmonization is intended to provide the reliability required for advanced analytics, enabling the pharmaceutical firm to accelerate its decision-making processes on a global scale.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!